shot-button
Subscription Subscription
Home > Entertainment News > Regional Indian Cinema News > Article > Rajinikanth 2o prestigious film for Indian cinema

Rajinikanth: '2.o' prestigious film for Indian cinema

Updated on: 21 November,2016 08:19 AM IST  | 
IANS |

Rajinikanth believes his upcoming Tamil science-fiction actioner '2.0' is not a prestigious film just for its makers but for the entire Indian cinema

Rajinikanth: '2.o' prestigious film for Indian cinema

Rajinikanth and Akshay Kumar in
Rajinikanth and Akshay Kumar in '2.0' poster. Picture courtesy film's Twitter account


Rajinikanth believes his upcoming Tamil science-fiction actioner '2.0' is not a prestigious film just for its makers but for the entire Indian cinema.


"I enjoyed working on this film. This subject is very unique. This is not just a prestigious picture for the producers, director Shankar or the unit but it's one for the whole Indian cinema," Rajinikanth said here at the first look launch event.


He's confident the Rs 350 crore mega budget film will match Hollywood standards.

"Despite our (Indian cinema's) technical excellence and the financial strength, we could not reach Hollywood standard yet. But I'm confident this film will reach Hollywood level. It'll be a film our entire Indian film fraternity will be proud of," he said.

Rajinikanth plays doctor-scientist Vaseegaran in the film, which is a sequel to his own 2010 blockbuster, 'Enthiran'.

Akshay Kumar is being introduced as the antagonist and he plays a scientist called Richard, who turns into a Crow Man after an experiment goes wrong.

Also starring Amy Jackson, Sudhanshu Pandey and Adil Hussain, the film is being completely shot in 3D, and is slated for Diwali 2017 release.

"Exciting news! Mid-day is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest news!" Click here!


Mid-Day Web Stories

Mid-Day Web Stories

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK